行业分析称 EU GMP Annex 1 正成为全球无菌药品生产参照基准
How local regulations are becoming global pharma manufacturing standards
Watson-Marlow 的 Sade Mokuolu 在分析文章中指出,2023 年 8 月生效的修订版 EU GMP Annex 1 由欧盟委员会与 PIC/S、WHO 共同制定,正从区域要求演变为事实上的全球无菌生产基准,Health Canada 已采用 PIC/S 版本并于 2024 年 4 月对加拿大许可持有人生效,日本、韩国、印尼也纳入了对齐要求。
![]()
Vials at the filling station of a Flexicon machine. [Watson-Marlow]
Ask a room of quality engineers what counts as a visible particle, and the discussion runs longer than you’d expect. What is the source of the particle? What is the size of the particle? Is it a visible particle? Is it a known particle present as a result of the drug formulation or environment? How is the particle characterized? How can drug manufacturers and suppliers work together to assess particulate risk through the product lifecycle? These are some of the questions an industry forum on particulates is trying to provide best practice guidance about. Controlling sources of contamination such as particulates is an increasingly important aspect of sterile manufacturing.
The rules governing how sterile drugs are made used to be written region by region. However, they are now converging, and much of that movement traces back to one European document. EU GMP Annex 1, the EU’s guidance on manufacturing sterile medicinal products, was revised to tighten contamination control and aseptic practice in Europe. Its influence now reaches well past the EU, into how drug makers design, validate and run fill-finish operations worldwide.
How regulations are converging
The revised Annex 1 took effect in August 2023, with one provision following a year later. It was never a purely European project; the European Commission developed it with the Pharmaceutical Inspection Co-operation Scheme (PIC/S) and the World Health Organization, and PIC/S published the same text. That made it the working reference for inspectorates in many countries on the same day.
National regulators have followed. Health Canada adopted the PIC/S version in its own sterile drug guidance, which came into force for Canadian licence holders in April 2024. Japan, South Korea and Indonesia have since built Annex 1-aligned requirements into their GMP rules.
As a result, Annex 1 is evolving from a regional GMP requirement into a de facto global benchmark, shaping the development of future regulatory guidance and raising expectations for both sterile and non-sterile pharmaceutical manufacturing operations.
Building a common framework
In most cases, drug companies will prepare a common core package which can be adapted to meet specific regulations. Typically, this would be in the form of a common technical document.
The Common Technical Document (CTD) is the harmonized dossier format developed by the International Council for Harmonisation (ICH) to enable pharmaceutical companies to submit a single core package of data when seeking marketing authorization in multiple countries. The CTD has been adopted by major regulatory authorities including the U.S. Food and Drug Administration (FDA) (2017), European Medicines Agency (EMA) (2003), Health Canada, SwissMedic, PMDA (Japan) (2003), and many other regulators. It consists of five modules covering administrative information, summaries, quality (CMC), non-clinical, and clinical data.
The value of the CTD is that a manufacturer can develop a global registration strategy using a common technical framework rather than preparing entirely different dossiers for each market. While country-specific administrative requirements remain and are detailed in Module 1, the scientific and technical content is largely harmonized. As regulatory agencies increasingly align their requirements around CTD and eCTD structures, the framework has become a critical enabler of global drug development, reducing submission complexity and promoting greater consistency in regulatory review.
Shaping standards
Although EU GMP Annex 1 is a manufacturing guideline rather than a registration standard, its influence is increasingly evident in the Quality Module (Module 3) of CTD submissions. Annex 1 has raised regulatory expectations for how manufacturers demonstrate contamination control, aseptic processing, and sterility assurance during product registration.
Key areas where Annex 1 is influencing CTD submissions include:
- Contamination Control Strategy (CCS): Regulators increasingly expect drug manufacturers to describe an integrated CCS encompassing facility design, utilities, equipment, personnel, environmental monitoring, cleaning, disinfection, and process controls. What was once primarily an inspection topic is now becoming part of the evidence package supporting product approval.
- Quality Risk Management (QRM): Annex 1 reinforces the principles of ICH Q9 Quality Risk Management, leading manufacturers to provide more comprehensive risk assessments within Module 3 to justify process design, monitoring frequencies, intervention strategies, and control limits.
- Process and Aseptic Validation: Greater emphasis is now placed on demonstrating robust aseptic process simulations, container closure integrity testing (CCIT), sterilization validation, and lifecycle monitoring. These data are increasingly scrutinized during both regulatory review and GMP inspections.
- Environmental Monitoring and Data Trending: Annex 1’s lifecycle approach requires manufacturers to present stronger scientific justification for environmental monitoring programs, action limits, alert limits, and contamination response plans.
- Use of Advanced Technologies: Regulators are becoming more receptive to technologies such as rapid microbial methods, automated environmental monitoring, digital contamination-control systems, and barrier technologies because Annex 1 explicitly encourages the use of modern, science-based approaches where appropriate.
At a 2024 PDA conference, Merck & Co. described the development of an integrated lifecycle Contamination Control Strategy (CCS) based on Quality Risk Management principles that could be applied consistently across manufacturing sites. The approach used standardized risk assessments, common CCS pillars, and structured controls to create a repeatable framework for sterile manufacturing operations. An area where the convergence is particularly evident is component qualification. In particular, the regulators increasingly align expectations around product quality, contamination control, data integrity, and supply chain oversight. Manufacturers are under greater pressure to demonstrate that critical components, raw materials, single-use systems, and packaging materials are fit for purpose throughout the product lifecycle. What began as region-specific expectations for supplier qualification and material control has evolved into a globally recognized requirement, with agencies placing increasing emphasis on risk-based qualification strategies, extractables and leachables assessment, change control, and supplier quality management.
![]()
A Flexicon FPC50 vial filling system with a single-use fluid path. [Watson-Marlow]
Component qualification follows the same logic. When a single-use assembly arrives with extractables data generated to a recognized industry protocol, the drug maker can use one data package to support filings in several regions rather than commissioning separate studies for each.
A useful parallel comes from large sterile manufacturing CDMOs that supply products into multiple regulatory jurisdictions. Companies such as PCI Pharma Services have publicly described using Annex 1 implementation as an opportunity to standardize contamination-control practices, barrier technologies, and sterile manufacturing systems across their North American and European fill-finish networks rather than maintaining region-specific approaches.
Regulators are comparing notes
Manufacturers aren’t the only ones converging. Regulators increasingly lean on each other’s work. PIC/S gives member inspectorates shared GMP texts, joint training and a common vocabulary for inspections. Health Canada helped draft the revised Annex 1 through PIC/S before adopting it at home.
The FDA is also a PIC/S member. It has not adopted Annex 1; its own aseptic processing guidance remains its main reference. But its investigators train and work alongside counterparts who inspect to Annex 1, and the US-EU mutual recognition agreement lets each side rely on the other’s GMP inspection reports.
While the regional differences remain, inspection expectations are drifting together. An observation a European inspector would raise is increasingly one an FDA investigator will ask about too.
Agreeing on what we’re measuring
Harmonized rules only help if everyone measures the same thing. That is the job of standards and industry organizations such as ASTM, ASME-BPE, the Bio-Process Systems Alliance and BioPhorum. They bring suppliers, drug makers and sometimes regulators together to agree on test methods, material requirements and validation approaches. I’ve contributed to several of these efforts, mostly on how single-use components are qualified.
The particle question shows why the detail matters. Pharmacopeial standards expect injectables to be essentially free of visible particles. Whether a batch passes, though, depends on definitions the rule leaves open: whether a particle adheres to the container wall counts, what size is visible, the origin, composition, and number of the particles.
Two sites can follow the same rule and reach different reject rates if they answer those questions differently. That’s why closing this gap is important: so inspection results mean the same thing from one site and one inspector to the next.
What this means for teams planning now
For anyone bringing a sterile product to more than one market, a few lessons follow.
First, design to the strictest requirement from the start. Retrofitting a process to a tougher standard costs more than building it in, and the validation work compounds as a product moves toward commercial scale.
Next, keep the process consistent as it grows. The fewer changes to equipment, parameters and components between clinical and commercial manufacture, the less revalidation you face and the fewer questions you field from inspectors.
Also, ask suppliers for documentation that works across jurisdictions: data generated to recognized industry protocols, lot traceability and clear change notification. That paperwork is what lets one validation package serve several regulators.

Sade Mokuolu, Ph.D.
And get involved in the standards conversation. Working groups need input from the people who run fill lines every day.
Annex 1 was written for Europe, but its lasting effect may be that it gave a global industry a shared reference point at a time when products, partners and inspections cross borders routinely.
Sade Mokuolu, Ph.D., is Regional Business Development Manager, Life Sciences, at Watson-Marlow Fluid Technology Solutions, where she works with drug manufacturers and CDMOs on fill-finish and fluid-path technologies. She previously held product compliance and strategy roles at Watson-Marlow and has contributed to industry work on single-use qualification and sustainability through groups including the Bio-Process Systems Alliance.
The post How local regulations are becoming global pharma manufacturing standards appeared first on Pharmaceutical Processing World.
来源:Pharmaceutical Processing World · pharmaceuticalprocessingworld.com